Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

194 DOXORUBICIN
(2006): Dasanu CA+, Dermatol Online J 12(6), 10 (with
vincristine and dexamethasone)
(1994): Ben-Dayan D+, Acta Haematol 91, 89
Nails – melanonychia
(2003): Khairkar PH, Indian Pediatr 40(11), 1094
Nails – Muehrcke’s lines
(2006): Dasanu CA+, Dermatol Online J 12(6), 10 (with
vincristine and dexamethasone)
Nails – onycholysis
(1990): Curran CF, Arch Dermatol 126, 1244
(1989): Jones AP+, Br J Cancer 59, 814
(1985): Kechijian P, JAmAcadDermatol12, 552
(1980): Runne U+, ZHaut(German) 55, 1590
Nails – pigmentation
(2006): Dasanu CA+, Dermatol Online J 12(6), 10 (with
vincristine and dexamethasone)
(1999): Ghoshal UC+, J Diarrhoeal Dis Res 17, 43
(1983): Bronner AK+, JAmAcadDermatol9, 645
(1983): James WD+, Arch Dermatol 119, 334 (white lines)
(1983): Manigand G+, Sem Hop (French) 59, 1840
(1982): Sans-Ortiz J+, Med Clin (Barc) (Spanish) 79, 49
(1981): Giacobetti R+, Am J Dis Child 135, 317
(1980): Runne U+, ZHaut(German) 55, 1590
(1980): Sulis E+, Eur J Cancer 16, 1517
Other
Anaphylactoid reactions/Anaphylaxis (5%)
Injection-site extravasation (>10%)
(2000): Kassner E, JPediatrOnconNurs17, 135
(2000): Lotem M+, Arch Dermatol 136, 1475
(1999): Fleming A+, JHandSurg[Br]24, 390
(1998): Emiroglu M+, Ann Plast Surg 41, 103
(1989): Harwood KV+, Oncol Nurs Forum 16, 10
(1984): Hankin FM+, J Pediatr Orthop 4, 96
(1984): Sonneveld P+, Cancer Treat Rep 68, 895
(1983): Cohen FJ+, JHandSurgAm8, 43
(1983): Olver IN+, Cancer Treat Rep 67, 407
(1983): Pitkanen J+, JSurgOncol23, 259
(1980): Barden GA, South Med J 73, 1543
Injection-site necrosis (>10%)
(1998): Bekerecioglu M+, JSurgRes75, 61
(1987): Dufresne RG, Cutis 39, 197
(1983): Bronner AK+, JAmAcadDermatol9, 645
Injection-site reactions
(2001): Verschraegen CF+, Cancer 92(9), 2327
Injection-site ulceration (>10%)
Myalgia/Myositis/Myopathy/Myotoxicity
(2002): Cantu MG+, J Clin Oncol 20(5), 1232 (4%) (with
cyclophosphamide and cisplatin)
DOXYCYCLINE
Trade names: Adoxa (Bioglan); Apo-Dox; Apo-Doxy; Atridox;
Azudoxat; Bactidox; Doryx (Warner Chilcott); Doximed; Doxy-
100; Doxylin; Doxytec; Monodox; Vibra-Tabs (Pfizer);
Vibramycin (Pfizer); Vibramycine; Vibravenos
Indications: Various infections caused by susceptible organisms
Category: Antibiotic, tetracycline
Half-life: 12–22 hours
Clinically important, potentially hazardous interactions
with: amoxicillin, ampicillin, antacids, bacampicillin, bismuth,
calcium, carbenicillin, cloxacillin, corticosteroids, digoxin, iron,
methoxyflurane, mezlocillin, nafcillin, oxacillin, penicillins,
piperacillin, retinoids, ticarcillin, zinc
Reactions
Skin
Actinic granuloma
(2003): Lim DS+, Australas J Dermatol 44(1), 67
Acute generalized exanthematous pustulosis (AGEP)
(1993): Trueb RM+, Dermatology 186, 75
Allergic reactions (sic) (0.47%)
(1986): Bigby M+, JAMA 256, 3358
Angioedema
(1997): Shapiro LE+, Arch Dermatol 133, 1224
Erythema multiforme
(1988): Lewis-Jones MS+, Clin Exp Dermatol 13, 245
(1987): Curley RK+, Clin Exp Dermatol 12, 124
(1985): Albengres E+, Therapie (French) 38, 577
Erythroderma
(2003): Batinac T+, Tumori 89(1), 91
Exanthems
(2003): Batinac T+, Tumori 89(1), 91
(1987): Bryant SG+, Pharmacotherapy 7, 125 (4.4%)
Exfoliative dermatitis
Fixed eruption (